Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 4/20 | 0.67 |
| ▸ | POLB | P06746 | 1/20 | 0.50 |
| ▸ | APOBEC3A | P31941 | 1/20 | 0.50 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.50 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.47 |
| ▸ | ESR1 | P03372 | 1/20 | 0.47 |
| ▸ | MMP2 | P08253 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15280427 | 1.00 | LMNA (0.67) | LMNAPOLBAPOBEC3AAPOBEC3GTDP1 | |
| SCHEMBL18041161 | 1.00 | LMNA (0.67) | LMNAPOLBAPOBEC3AAPOBEC3GTDP1 | |
| SCHEMBL15280428 | 1.00 | LMNA (0.67) | LMNAPOLBAPOBEC3AAPOBEC3GTDP1 | |
| SCHEMBL28751377 | 0.90 | LMNA (0.52) | LMNAPOLBAPOBEC3AAPOBEC3GTDP1 | |
| SCHEMBL16450976 | 0.90 | LMNA (0.67) | LMNAPOLBAPOBEC3AAPOBEC3GTDP1 | |
| SCHEMBL16450981 | 0.90 | LMNA (0.67) | LMNAPOLBAPOBEC3AAPOBEC3GTDP1 | |
| SCHEMBL15280430 | 0.90 | LMNA (0.67) | LMNAPOLBAPOBEC3AAPOBEC3GTDP1 | |
| SCHEMBL927698 | 0.88 | ESR1 (0.57) | LMNAPOLBAPOBEC3AAPOBEC3GTDP1 | |
| SCHEMBL13986553 | 0.88 | MCL1 (0.62) | LMNAPOLBAPOBEC3AAPOBEC3GTDP1 | |
| SCHEMBL20920601 | 0.87 | LMNA (0.53) | LMNAPOLBAPOBEC3AAPOBEC3GTDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4011454-A1 | DUAL FUNCTION MOLECULES FOR HISTONE DEACETYLASE INHIBITION AND ATAXIA TELANGIECTASIA MUTATED ACTIVATION | Shuttle Pharmaceuticals, Inc. (US) | 2022-06-15 | — | — | EP | disclosed |
| US-20220055988-A1 | DUAL FUNCTION MOLECULES FOR HISTONE DEACETYLASE INHIBITION AND ATAXIA TELANGIECTASIA MUTATED ACTIVATION AND METHODS OF USE THEREOF | SHUTTLE PHARMACEUTICALS INC (US) | 2022-02-24 | — | — | US | disclosed |
| EP-3265073-B1 | DUAL FUNCTION MOLECULES FOR HISTONE DEACETYLASE INHIBITION AND ATAXIA TELANGIECTASIA MUTATED ACTIVATION AND METHODS OF USE THEREOF | SHUTTLE PHARMACEUTICALS INC (US) | 2021-08-18 | — | — | EP | disclosed |
| US-20200317611-A1 | DUAL FUNCTION MOLECULES FOR HISTONE DEACETYLASE INHIBITION AND ATAXIA TELANGIECTASIA MUTATED ACTIVATION AND METHODS OF USE THEREOF | SHUTTLE PHARMACEUTICALS INC (US) | 2020-10-08 | — | — | US | disclosed |
| US-10745352-B2 | Dual function molecules for histone deacetylase inhibition and ataxia telangiectasia mutated activation and methods of use thereof | SHUTTLE PHARMACEUTICALS, INC. (US) | 2020-08-18 | — | — | US | disclosed |
| US-10730834-B2 | Dual function molecules for histone deacetylase inhibition and ataxia telangiectasia mutated activation and methods of use thereof | SHUTTLE PHARMACEUTICALS, INC. (US) | 2020-08-04 | — | — | US | disclosed |
| US-20180057456-A1 | DUAL FUNCTION MOLECULES FOR HISTONE DEACETYLASE INHIBITION AND ATAXIA TELANGIECTASIA MUTATED ACTIVATION AND METHODS OF USE THEREOF | SHUTTLE PHARMACEUTICALS, INC. | 2018-03-01 | — | — | US | disclosed |
| US-20180044292-A1 | DUAL FUNCTION MOLECULES FOR HISTONE DEACETYLASE INHIBITION AND ATAXIA TELANGIECTASIA MUTATED ACTIVATION AND METHODS OF USE THEREOF | SHUTTLE PHARMACEUTICALS, INC. | 2018-02-15 | — | — | US | disclosed |
| US-9809539-B2 | Dual function molecules for histone deacetylase inhibition and ataxia telangiectasia mutated activation and methods of use thereof | SHUTTLE PHARMACEUTICALS, LLC (US) | 2017-11-07 | — | — | US | disclosed |
| US-20160257649-A1 | DUAL FUNCTION MOLECULES FOR HISTONE DEACETYLASE INHIBITION AND ATAXIA TELANGIECTASIA MUTATED ACTIVATION AND METHODS OF USE THEREOF | SHUTTLE PHARMACEUTICALS, LLC | 2016-09-08 | — | — | US | disclosed |
| US-7166580-B2 | Compounds which inhibit leukocyte adhesion mediated by VLA-4 | ELAN PHARMACEUTICALS, INC. (US) | 2007-01-23 | — | — | US | disclosed |
| US-20030166575-A1 | Compounds which inhibit leukocyte adhesion mediated by VLA-4 | BIOGEN MA INC. | 2003-09-04 | — | — | US | disclosed |
| US-6559127-B1 | Intercellular adhesion mediated by VLA-4 and other cell surface receptors is associated with a number of inflammatory responses | ATHENA NEUROSCIENCES, INC. | 2003-05-06 | — | — | US | disclosed |
| EP-1001973-A1 | COMPOUNDS WHICH INHIBIT LEUKOCYTE ADHESION MEDIATED BY VLA-4 | Elan Pharmaceuticals, Inc. (US) | 2000-05-24 | — | — | EP | disclosed |
| WO-1999006433-A1 | COMPOUNDS WHICH INHIBIT LEUKOCYTE ADHESION MEDIATED BY VLA-4 | ELAN PHARMACEUTICALS, INC. (US) | 1999-02-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180044292-A1 | DUAL FUNCTION MOLECULES FOR HISTONE DEACETYLASE INHIBITION AND ATAXIA TELANGIECTASIA MUTATED ACTIVATION AND METHODS OF USE THEREOF | ATM, HDAC8, HDAC1 | LMNA 1551/4885POLB 156/4885APOBEC3A 1989/4885 |
| US-20180057456-A1 | DUAL FUNCTION MOLECULES FOR HISTONE DEACETYLASE INHIBITION AND ATAXIA TELANGIECTASIA MUTATED ACTIVATION AND METHODS OF USE THEREOF | ATM, HDAC8, HDAC1 | LMNA 1551/4885POLB 156/4885APOBEC3A 1989/4885 |
| US-10745352-B2 | Dual function molecules for histone deacetylase inhibition and ataxia telangiectasia mutated activation and methods of use thereof | ATM, HDAC8, HDAC1 | LMNA 1551/4885POLB 156/4885APOBEC3A 1989/4885 |
| US-20200317611-A1 | DUAL FUNCTION MOLECULES FOR HISTONE DEACETYLASE INHIBITION AND ATAXIA TELANGIECTASIA MUTATED ACTIVATION AND METHODS OF USE THEREOF | ATM, HDAC8, HDAC1 | LMNA 1551/4885POLB 156/4885APOBEC3A 1989/4885 |
| US-20030166575-A1 | Compounds which inhibit leukocyte adhesion mediated by VLA-4 | VCAM1, ICAM1, CD4 | LMNA 3701/4885POLB 3968/4885APOBEC3A 4607/4885 |
| US-20160257649-A1 | DUAL FUNCTION MOLECULES FOR HISTONE DEACETYLASE INHIBITION AND ATAXIA TELANGIECTASIA MUTATED ACTIVATION AND METHODS OF USE THEREOF | ATM, HDAC8, HDAC1 | LMNA 1551/4885POLB 156/4885APOBEC3A 1989/4885 |
| US-10730834-B2 | Dual function molecules for histone deacetylase inhibition and ataxia telangiectasia mutated activation and methods of use thereof | ATM, HDAC8, HDAC1 | LMNA 1551/4885POLB 156/4885APOBEC3A 1989/4885 |
| US-20220055988-A1 | DUAL FUNCTION MOLECULES FOR HISTONE DEACETYLASE INHIBITION AND ATAXIA TELANGIECTASIA MUTATED ACTIVATION AND METHODS OF USE THEREOF | ATM, HDAC8, HDAC1 | LMNA 1551/4885POLB 156/4885APOBEC3A 1989/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.